SPR Therapeutics announces positive data for PNS pain relief device

SPR Therapeutics announced positive results from a study evaluating its peripheral nerve stimulation (PNS) device for alleviating chronic knee pain post knee replacement surgery. The trial focused on the SPRINT PNS system's efficacy over 60 days in patients with persistent postoperative pain after total knee arthroplasty (TKA). Approximately 20% of TKA patients experience prolonged pain. The device uses percutaneous PNS to target peripheral nerves, delivering electrical pulses to modify pain signal transmission to the brain. FDA-approved for chronic pain relief, it outperformed a placebo in the trial. Sixty percent of PNS recipients achieved over 50% pain relief, compared to 24% in the placebo group. PNS recipients also showed a 47% improvement in walking ability. No significant adverse events were reported. This study reinforces the potential of PNS as a non-opioid option for managing chronic knee pain post-surgery.